Can Pfizer (PFE) Stock Reach $35?

Key Takeaways

• The $35 objective used here is a fallback target drawn from public market discussion — specifically the upper end of the analyst price-target range and ongoing commentary around Pfizer's turnaround — not an official analyst consensus.
• Pfizer shares last closed near $30.52, meaning reaching $35 would require a roughly 15% gain, a substantial but not extreme move.
• The average of all valid analyst price targets reviewed is roughly $29, below the current price, with individual targets spanning approximately $25 to $35 (some compilations show a high near $36).
• Key supports include a multi-billion-dollar cost-reduction program, raised full-year revenue guidance, and a rebuilding oncology and weight-loss pipeline.
• The central risks are a looming patent cliff and a projected earnings decline in 2027, which could weigh on valuation after the recent rally.
• You can find more detail on Pfizer's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
• Explore Trending AI Robots to see AI-driven tools monitoring stocks like PFE in real time.

Analyst Price Targets and How the $35 Level Was Set

Pfizer Inc. (PFE) is a global biopharmaceutical company, not an exchange-traded fund. After a strong run that took the stock to a 52-week high, the shares now trade above their average analyst price target, so a conventional consensus figure does not provide a meaningful upside objective here.

Across roughly 16 current, attributed targets reviewed, individual forecasts range from about $25 (RBC Capital) to $35 (Argus), with most clustered between $26 and $33. Recent actions include JPMorgan at $30, Scotiabank at $33, HSBC at $30, and Guggenheim trimming its target to $31. The arithmetic mean of these targets is approximately $29, in line with independently reported consensus figures of roughly $29 — below the latest price. Even averaging only the targets above the current price ($31, $33, $33, $34, and $35) yields about $33, less than the roughly 10% threshold needed for a meaningful central target.

For that reason, the $35 figure used in this article is a fallback objective grounded in public discussion: it sits near the top of the analyst range, matches Argus's Buy target, and reflects a level Guggenheim recently held before trimming. It is presented as a realistic objective under debate, not a consensus forecast.

Current Market Position and Path Toward the Target

Pfizer shares closed near $30.52, up roughly 25% over the trailing 52 weeks and at a fresh 52-week high. Reaching $35 implies a gain of about 15% from that level. The path would likely depend on Pfizer converting its recent operational improvement into durable earnings growth as it approaches a wave of patent expirations.

The company raised its full-year 2026 revenue guidance to a range of $60.5 billion to $62.5 billion, lifting the low end by $1 billion, and is pursuing up to $6.7 billion in cumulative cost savings by 2029. Pfizer's next earnings report is scheduled for early November, a near-term catalyst that could recalibrate expectations on both revenue momentum and pipeline progress.

What Could Support a Move Toward the Target

• Cost discipline: the $6.7 billion savings program could protect margins and support a re-rating of the forward P/E (price-to-earnings) ratio.
• Raised guidance: the higher 2026 revenue floor signals better-than-expected commercial execution across key franchises.
• Pipeline optionality: oncology assets and an emerging weight-loss (GLP-1) portfolio are the most frequently cited reasons for above-market targets.
• Income support: a dividend yielding around 5.6% and a low beta of roughly 0.2 to 0.3 give defensive investors a reason to hold through volatility.

What Could Prevent the Target From Being Reached

• Patent cliff: loss of exclusivity (LOE) on major products is the dominant bear case, with sell-side models projecting EPS (earnings per share) to dip from roughly $2.96 in 2026 to about $2.88 in 2027.
• Valuation after the rally: the trailing P/E near 40 and the run to a 52-week high leave limited room for error if guidance disappoints.
• Competition and regulatory risk: pricing pressure and rivals in oncology and metabolic disease could limit new-product uptake.
• Analyst caution: a Hold-leaning consensus and several targets below the current price suggest the Street already prices in much of the recovery.

Technical Levels and Market Structure

Pfizer's 52-week range runs roughly from $23.62 to about $30.67. The stock is trading near the top of that range after clearing prior resistance around the $28 to $29 zone, a level that could now act as support on pullbacks. The $35 mark is a round-number psychological level and sits just below the upper boundary of the analyst target range, while Pfizer's 2021 all-time high near $61.71 remains far above and is not a relevant near-term reference.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of about 12 months, though individual firms may differ. Investors weighing the path to $35 should watch the November earnings release and guidance, any further analyst revisions to the 2027 earnings outlook, clinical and regulatory updates on the oncology and GLP-1 pipelines, and signs that the cost-savings program is tracking ahead of schedule. Shifts in the broader healthcare sector and interest-rate expectations also matter for a dividend-paying large-cap.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. Rather than replacing research, the tool helps traders discover opportunities, track positions, and spot emerging trend changes more efficiently across a broad universe. For investors following Pfizer and other large-cap names, pairing fundamental analysis with AI-generated signals can offer an additional, objective layer of perspective when timing entries and exits.

Final Assessment

The $35 target for Pfizer is not an analyst consensus but a fallback objective rooted in public discussion near the top of the Street's range. It implies a roughly 15% advance from the latest price near $30.52 — attainable only if the company's cost savings, raised guidance, and pipeline momentum outweigh the patent cliff and a projected 2027 earnings dip. With a Hold-leaning consensus and an average target below the current price, opinion is divided: bulls point to a credible turnaround, while skeptics argue much of the recovery is already reflected in the stock. The November earnings report and subsequent analyst revisions will be the most important near-term signposts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations